Saturday, October 10, 2026

Back to today

From X

@calvinblissett

Calvin Blissett on X

$FF: $195m EV, 30-40m current EBITDA est at RIN prices. 30m in hidden Arkansas land value (1.7k A out of 2.2k not being used) Thesis: Future Fuel's economics are primarily a bet on biodiesel margins. FF owns a relatively high-cost 59-million-gallon-per-year biodiesel plant, so it generally needs stronger industry margins than larger competitors to justify running at high utilization. The reason a high-cost producer like FF can still matter is the Renewable Fuel Standard (RFS): refiners must satisfy EPA-mandated renewable-fuel volumes, either by blending fuel or acquiring RIN credits. When mandated demand approaches or exceeds economical industry supply, the D4 RIN price rises until the marginal/high-cost producers have enough incentive to restart. FF is one of those marginal producers. That is the core thesis today. D4 RINs have risen sharply from roughly $0.50 in the depressed period to around $1.50, reflecting tighter expected supply/demand, while the EPA's much higher 2026–27 requirements should require substantially more biomass-based diesel production. If the industry remains short of required supply and the RIN bank is drawn down, RINs and therefore biodiesel margins should remain high enough to keep FF operating profitably; roughly speaking, every $0.10/gallon of sustainable margin on ~50 million gallons equals ~$5 million of annual operating profit. A return toward $0.30–$0.50/gallon margins could mean ~$15–25 million of biodiesel operating profit, versus very little or losses when margins collapse. The catalysts are higher plant utilization, continued tight D4 RIN supply/2027 RIN-bank depletion, and stronger chemicals earnings; the major risk is the opposite—RIN prices fall because supply increases, EPA policy weakens demand, exemptions expand, or renewable-diesel capacity overwhelms the market. In simple terms: FF is the expensive factory that the market may now need to run, and the RIN price is effectively what determines whether it gets paid enough to do so.

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

Not So Fast

Entravision, the portfolio’s largest position, fell more than 40% from its highs as Q3 returns dropped to 37.8% YTD.

BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

Solid Power Still Has Promise

Solid Power reported a $0.11 Q2 loss and $419.3 million of cash, with its electrolyte pilot line and BMW and SK On validation central to…

Zentek Research Note

Zentek shipped its first ZenGUARD air-filter order to a Canadian federal facility as its Albany graphite PEA confirmed a US$3.85 billion…

💥Yield!💥

Beyond Meat’s Q2 2026 revenue fell 8.2% as U.S. retail and foodservice volumes declined, while a flatter, not inverted, Treasury curve…

Updates

FGPR remains on track, PRTH's management buyout is set at $8.05, and microcap RAVE is described as cheap.

Is The Bond Market Running On Empty?

U.S. Treasury yields are testing credit and equity markets, while the discussion also targets recent changes at Glass House (GLAS).

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

X accounts we follow

Every account on this site, hand-picked.

74 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.